[go: up one dir, main page]

MA70477B1 - Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques - Google Patents

Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques

Info

Publication number
MA70477B1
MA70477B1 MA70477A MA70477A MA70477B1 MA 70477 B1 MA70477 B1 MA 70477B1 MA 70477 A MA70477 A MA 70477A MA 70477 A MA70477 A MA 70477A MA 70477 B1 MA70477 B1 MA 70477B1
Authority
MA
Morocco
Prior art keywords
treatment
amido
hetero
liver diseases
compounds useful
Prior art date
Application number
MA70477A
Other languages
English (en)
Inventor
Daniel Tor Pettersen
Erik Lars MALMERBERG
Tord Bertil Inghardt
Jan Åke LINDBERG
Jens Peter BRANDT
Björn Erik Anton HOLM
Stéphanie Marcelle GUERET
Nidhal SELMI
Jon Paul JANET
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA70477B1 publication Critical patent/MA70477B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I) : et des sels pharmaceutiquement acceptables de ceux-ci, des procédés et des intermédiaires utilisés pour leur préparation, des compositions pharmaceutiques les contenant et leur utilisation dans le traitement de maladies telles que les maladies hépatiques.
MA70477A 2022-05-19 2023-05-18 Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques MA70477B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263364976P 2022-05-19 2022-05-19
US202263367843P 2022-07-07 2022-07-07
US202263383982P 2022-11-16 2022-11-16
EP23727858.5A EP4514782B1 (fr) 2022-05-19 2023-05-18 Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques
PCT/EP2023/063424 WO2023222850A1 (fr) 2022-05-19 2023-05-18 Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques

Publications (1)

Publication Number Publication Date
MA70477B1 true MA70477B1 (fr) 2025-12-31

Family

ID=86646721

Family Applications (1)

Application Number Title Priority Date Filing Date
MA70477A MA70477B1 (fr) 2022-05-19 2023-05-18 Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques

Country Status (25)

Country Link
US (2) US20230373983A1 (fr)
EP (2) EP4514782B1 (fr)
JP (1) JP7770594B2 (fr)
KR (1) KR20250016177A (fr)
CN (1) CN119173506A (fr)
AU (1) AU2023274003B2 (fr)
CA (1) CA3256765A1 (fr)
CL (1) CL2024003495A1 (fr)
CO (1) CO2024017138A2 (fr)
CR (1) CR20240536A (fr)
DK (1) DK4514782T3 (fr)
DO (1) DOP2024000239A (fr)
FI (1) FI4514782T3 (fr)
HR (1) HRP20251564T1 (fr)
IL (1) IL316898A (fr)
LT (1) LT4514782T (fr)
MA (1) MA70477B1 (fr)
MX (1) MX2024014315A (fr)
PE (1) PE20250791A1 (fr)
PT (1) PT4514782T (fr)
RS (1) RS67515B1 (fr)
SM (1) SMT202500465T1 (fr)
TW (1) TW202411224A (fr)
UY (1) UY40282A (fr)
WO (1) WO2023222850A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025104697A1 (fr) 2023-11-16 2025-05-22 Astrazeneca Ab Inhibiteurs de la 17-bêta-hydroxystéroïde déshydrogénase 13 hétéroaromatiques
TW202521529A (zh) * 2023-11-16 2025-06-01 瑞典商阿斯特捷利康公司 脲嘧啶化合物
WO2025104564A1 (fr) * 2023-11-16 2025-05-22 Astrazeneca Ab Forme cristalline d'un composé amido hétéroaromatique

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1030415A (zh) 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
JPH0696532B2 (ja) 1988-08-11 1994-11-30 山之内製薬株式会社 血小板活性化因子拮抗剤
US7074809B2 (en) 2002-08-09 2006-07-11 Astrazeneca Ab Compounds
IL166510A0 (en) 2002-08-09 2006-01-15 Nps Pharma Inc 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5
AR041508A1 (es) 2002-08-09 2005-05-18 Astra Ab Compuestos con actividad en los receptores de glutamato metabotropicos
WO2005077345A1 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Composes pour le traitement de la maladie du reflux gastro-oesophagien
WO2005077368A2 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Nouveau traitement du reflux gastro-oesophagien pathologique iii
WO2005077373A2 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Nouveau traitement du reflux gastro-oesophagien pathologique ii
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
AU2008257158A1 (en) 2007-05-22 2008-12-04 Achillion Pharmaceuticals, Inc. Heteroaryl substituted thiazoles and their use as antiviral agents
EP2002834A1 (fr) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryle/hétarylamides en tant que modulateurs du récepteur EP2
CA2716320C (fr) 2008-02-22 2014-01-28 Radius Health, Inc. Modulateurs selectifs du recepteur de l'androgene
WO2009126782A1 (fr) 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Ligands du récepteur h<sb>3</sb> de l'histamine
US20100144733A1 (en) 2008-04-28 2010-06-10 Institute For Oneworld Health Compounds, compositions and methods comprising heteroaromatic derivatives
US20090318429A1 (en) 2008-04-28 2009-12-24 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives
JP2012505898A (ja) 2008-10-16 2012-03-08 シェーリング コーポレイション ピロリジン、ピペリジンおよびピペラジン誘導体ならびにそれらの使用方法
EP2550266B1 (fr) 2010-03-24 2018-05-09 Amitech Therapeutics Solutions, Inc. Composés hétérocycliques utiles pour l'inhibition de la kinase
KR101559883B1 (ko) 2013-10-30 2015-10-13 동국대학교 산학협력단 2-아미노치환 옥사디아졸 유도체, 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2015090579A1 (fr) 2013-12-18 2015-06-25 Grünenthal GmbH Carboxamides à base de pyrazolyle servant d'inhibiteurs de canal crac
US20170290337A1 (en) 2014-09-24 2017-10-12 Syngenta Participations Ag Herbicidal Pyridino-/Pyrimidino-Thiazoles
US10865181B2 (en) 2014-11-05 2020-12-15 University Of Kansas Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP)
WO2016172631A2 (fr) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Inhibiteurs sélectifs de substrats d'enzyme dégradant l'insuline (ide) et utilisations associées
SMT202300273T1 (it) 2016-03-16 2023-09-06 Kura Oncology Inc Derivati di tieno[2,3–d]pirimidina sostituiti come inibitori di menina–mll e metodi d’uso
US11135207B2 (en) 2016-12-13 2021-10-05 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease
MX2019014875A (es) 2017-06-21 2021-01-29 SHY Therapeutics LLC Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
US11795162B2 (en) * 2017-08-18 2023-10-24 Saint Louis University Modulators of the estrogen-related receptor
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
MA52365A (fr) 2018-04-25 2021-03-03 Yumanity Therapeutics Inc Composés et leurs utilisations
KR20210071976A (ko) 2018-09-04 2021-06-16 마젠타 테라퓨틱스 인코포레이티드 아릴 하이드로카본 수용체 길항제 및 사용 방법
WO2020156241A1 (fr) 2019-01-31 2020-08-06 中国医药研究开发中心有限公司 Composés cycliques aromatiques ou cycliques hétéroaromatiques, procédé de préparation correspondant et utilisation médicale associée
EP3994125B1 (fr) 2019-07-02 2025-12-24 Regeneron Pharmaceuticals, Inc. Modulateurs de hsd17b13 et leurs procédés d'utilisation
WO2021050555A1 (fr) 2019-09-10 2021-03-18 X-Chem, Inc. Compositions et leurs utilisations
WO2021138450A1 (fr) 2019-12-30 2021-07-08 Buto Corporation Nouveaux bloqueurs de shc à petites molécules pour le traitement d'une maladie hépatique et d'une maladie métabolique
WO2021211974A1 (fr) 2020-04-18 2021-10-21 Inipharm, Inc. Composés et utilisations de ceux-ci
IL298475A (en) * 2020-06-09 2023-01-01 Anima Biotech Inc Collagen-1 translation inhibitors and methods of their use
US20230278978A1 (en) * 2020-07-24 2023-09-07 Inipharm, Inc. Thiophene hsd17b13 inhibitors and uses thereof
AU2021310936A1 (en) * 2020-07-24 2023-03-09 Inipharm, Inc. Quinazolinone HSD17B13 inhibitors and uses thereof
CA3190258A1 (fr) 2020-08-18 2022-02-24 Metrea Biosciences, Inc. Composes et procedes de modulation de la 17.beta.-hydroxysteroide deshydrogenase de type 13
MX2023003678A (es) * 2020-09-30 2023-06-22 Fl2022 001 Inc Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
JP2023544157A (ja) * 2020-09-30 2023-10-20 エフエル２０２２－００１， インコーポレイテッド Ｈｓｄ１７ｂ１３阻害剤及びその使用
CN116744918A (zh) * 2020-09-30 2023-09-12 Fl2022-001公司 Hsd17b13抑制剂和其用途
IL302764A (en) 2020-11-13 2023-07-01 Inipharm Inc Dichlorophenol HSD17B13 inhibitors and their uses
US20240132431A1 (en) 2021-01-06 2024-04-25 Chugai Seiyaku Kabushiki Kaisha Method for alkylating acidic functional group
US20250154686A1 (en) 2021-01-06 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Compound library
EP4319872A4 (fr) 2021-04-05 2025-03-12 Inipharm, Inc. Inhibiteurs d'hsd17b13 de type thiazole/isothiazole et leurs utilisations
US20240208929A1 (en) 2021-04-05 2024-06-27 Inipharm, Inc. Hydroxypyridine hsd17b13 inhibitors and uses thereof
US20220380378A1 (en) 2021-04-22 2022-12-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
BR112023025112A2 (pt) 2021-06-01 2024-02-20 Syngenta Crop Protection Ag Derivados microbiocidas de tetrahidroisoquinolina
US20250100993A1 (en) 2022-01-26 2025-03-27 Inipharm, Inc. 2-substituted thiazole hsd17b13 inhibitors and uses thereof

Also Published As

Publication number Publication date
EP4635494A2 (fr) 2025-10-22
US12291524B2 (en) 2025-05-06
KR20250016177A (ko) 2025-02-03
PT4514782T (pt) 2025-12-15
JP2025516080A (ja) 2025-05-26
WO2023222850A1 (fr) 2023-11-23
US20250011311A1 (en) 2025-01-09
CL2024003495A1 (es) 2025-04-04
SMT202500465T1 (it) 2026-01-12
MX2024014315A (es) 2024-12-06
AU2023274003B2 (en) 2026-01-29
EP4514782B1 (fr) 2025-09-10
AU2023274003A1 (en) 2025-01-02
CR20240536A (es) 2025-01-29
DK4514782T3 (da) 2025-12-15
DOP2024000239A (es) 2024-12-30
HRP20251564T1 (hr) 2026-01-30
LT4514782T (lt) 2025-12-29
EP4635494A3 (fr) 2025-12-31
UY40282A (es) 2023-11-15
PE20250791A1 (es) 2025-03-14
IL316898A (en) 2025-01-01
CA3256765A1 (fr) 2023-11-23
JP7770594B2 (ja) 2025-11-14
RS67515B1 (sr) 2025-12-31
EP4514782A1 (fr) 2025-03-05
FI4514782T3 (fi) 2025-12-10
TW202411224A (zh) 2024-03-16
CN119173506A (zh) 2024-12-20
US20230373983A1 (en) 2023-11-23
CO2024017138A2 (es) 2025-03-06

Similar Documents

Publication Publication Date Title
MA70477B1 (fr) Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
MA28747B1 (fr) Dérivés de pyridine
TN2009000138A1 (fr) Biaryl-ether-urees
MA29926B1 (fr) Derives de pyrazine
MA58498B1 (fr) Agonistes hétérocycliques de glp-1
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA59968B1 (fr) Composés de cyclobutyle dihydroquinoléine sulfonamide
MA31419B1 (fr) Derives de pyridine
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA54608B1 (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d&#39;utilisation pour le traitement du cancer
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA30403B1 (fr) Derives d&#39;acides cycloalkylamines et leurs compositions pharmaceutiques
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA27808A1 (fr) Derives de quinoleine utilises en tant qu&#39;inhibiteurs de la phosphodiesterase
MA27801A1 (fr) Nouveaux composes heterocycliques pour le traitement des affections inflammatoires et allergiques, leur procede de preparation et compositions pharmaceutiques les contenant
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
MA38138A1 (fr) Dérivés inédits de quinolone
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA27990A1 (fr) Derives de piperazine pour le traitement d&#39;infections par le vih
MA30232B1 (fr) Inhibiteurs de kinase bases sur l&#39;hydantoine
MA27095A1 (fr) Formes de sels de e-2 -methoxy-n-(3-(4-(3-methyl-pyridine-3-yloxy)-phenylamino)-quinazoline-6-yl)-allyl)-acetamide, leur preparation et leur utilisation contre le cancer
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu&#39;inhibiteurs de kinase jak
MA30696B1 (fr) Derives de l&#39;acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique